prognosis factors
Recently Published Documents


TOTAL DOCUMENTS

282
(FIVE YEARS 95)

H-INDEX

30
(FIVE YEARS 4)

ASJ. ◽  
2021 ◽  
Vol 1 (56) ◽  
pp. 21-24
Author(s):  
M. Tillashaykhov ◽  
L. Gaziev ◽  
D. Almuradova

This article analyzes the main clinical, morphological factors affecting the outcome of the disease, and determines their proportion. Favorable clinical and morphological signs were: absence of lymphovascular invasion, lymphocytic infiltration of the tumor, small tumor size, absence of concomitant pathology. Adverse prognosis factors include: lymphovascular invasion, absence of tumor infiltration by lymphocytes, large tumor size and severe concomitant pathologies.


2021 ◽  
Vol 2 (4) ◽  
pp. 155-162
Author(s):  
John L. Yovich ◽  
Peter M. Hinchliffe

Since 2010, numerous studies reported from PIVET, a pioneer IVF facility established over 40 years ago, have explored the use of three adjuvants designed to improve laboratory and clinical outcomes in cases where a poor prognosis has been demonstrated. The adjuvants reported commenced with recombinant growth hormone (rGH), followed by dehydroepiandrosterone (DHEA) after developing a unique troche to avoid the first-pass effect and, subsequently, melatonin. The studies show that rGH is beneficial in the situation where women have poor-quality embryos in the setting of additional poor prognosis factors, such as advanced female age, a very low ovarian reserve, an insulin growth factor profile in the lowest quartile or recurrent implantation failure. The studies also imply that the adjuvants may actually reduce live birth productivity rates if used on women without poor prognosis factors; hence, further studies, which can now be better designed, should be undertaken to explore the notion of underlying adult growth hormone deficiency in some cases as well as the suggestion that DHEA can provide equivalent benefits in some poor prognosis settings. Melatonin showed no suggestive benefits in any of the studies and can be excluded from consideration in this context. Future studies should compare rGH and DHEA with a focus on those women who have poor embryo quality with additional poor prognosis factors. Such trials should be extended to 12 weeks to cover the entire period of oocyte activation.


2021 ◽  
Vol 43 ◽  
pp. S15-S16
Author(s):  
Larisa Musteata ◽  
Ion Corcimaru ◽  
Vasile Musteata
Keyword(s):  

2021 ◽  
Author(s):  
Yanqing Zhang ◽  
Jiaqi Pan ◽  
Xi Chen ◽  
Lianjie Wang ◽  
Liyan Chen ◽  
...  

Aim: Increased serum ferritin (SF) indicates an adverse prognosis in patients with hematologic malignancies. However, its prognostic significance in multiple myeloma (MM) remains unknown. Patients & methods: The impact of SF levels on outcomes in patients with MM was retrospectively analyzed and dynamically assessed. Results: At initial diagnosis, 188 out of 295 patients (63.7%) had high SF that correlated with poor prognosis factors including adverse overall survival and progression-free survival. SF expression was dynamically observed at different time points and SF levels significantly decreased after treatment induction. In addition, SF expression significantly increased at disease progression or relapse. Conclusion: SF can be used as a prognostic factor at initial diagnosis and relapse in patients with MM.


2021 ◽  
Vol 429 ◽  
pp. 119647
Author(s):  
Carlos Catedra Carame ◽  
Laura Amaya Pascasio ◽  
Andres Garcia Pastor ◽  
Ana María Iglesias Mohedano ◽  
Fernando Diaz Otero ◽  
...  

2021 ◽  
Vol 82 (5) ◽  
pp. 243
Author(s):  
C. Roux ◽  
A. Boileve ◽  
M. Faron ◽  
E. Mathy ◽  
L. Lamartina ◽  
...  

2021 ◽  
Vol 5 (9) ◽  
pp. 890-896
Author(s):  
Shinta Qorina ◽  
Wirsma Arif Harahap ◽  
Ricvan Dana Nindrea

Introduction: Breast cancer is the most common malignancy that occurs in women in the world, which is about 18% of cancer cases that occur in women. Every year there are 1 million new cases of breast cancer worldwide and nearly 60,000 patients die from this disease. Therefore, the authors want to find out more about the prognosis factors that play a role in influencing the survival of patients with locally advanced breast cancer in Padang city, West Sumatera Province Indonesia. Methods: This study is a retrospective case-control study of locally advanced breast cancer for patients in Padang city. The study was conducted at the Surgical Oncology Division of Dr. M Djamil Padang Hospital, Ropana Suri Hospital, Ibnu Sina Hospital and Siti Rahmah Padang Hospital from September 2018 to December 2018. The total number of samples for the two groups was 242 people. The sampling technique used was convenience sampling. Results: In this study 4 prognostic factors were found that had a significant effect on predicting breast cancer recurrence, namely histopathological type, stage, regional lymph and lymphovascular invasion with p <0.05. Conclusion: Prognosis factors that influence breast cancer recurrence are histopathological type, stage, regional lymph node status and lymphovascular invasion. A scoring system is obtained that is good enough to predict the possibility of breast cancer recurrence.


Sign in / Sign up

Export Citation Format

Share Document